



Humira Drug Formulary Change

This letter is to inform you about some important changes that are taking place regarding Humira®, an injectable biologic used to treat various inflammatory conditions such as rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurative. Effective 1/1/2026, Humira® will be removed from our Medicare formulary. Our new preferred injectable biologics will include Adalimumab-fkjp and Simlandi, interchangeable biosimilars of Humira® used to treat the same indications.

If your patient is already taking Humira®, please consider changing to one of our formulary alternatives listed below to avoid any interruption in care. Please note that the new formulary biosimilars in the table below will require a prior authorization for 2026.

Our alternatives for Humira® that will be on formulary with prior authorization effective 1/1/2026 include:

include.	
Tier	Notes and Restrictions
3	Prior Authorization; Quantity
	Limit 6/28-day
3	Prior Authorization; Quantity
	Limit 4/28-day
3	Prior Authorization; Quantity
	Limit 6/28-day
3	Prior Authorization; Quantity
	Limit 6/28-day
3	Prior Authorization; Quantity
	Limit 3/28-day
3	Prior Authorization; Quantity
	Limit 3/28-day
3	Prior Authorization; Quantity
	Limit 6/28-day
3	Prior Authorization; Quantity
	Limit 4/28-day
3	Prior Authorization; Quantity
	Limit 6/28-day
	3 3 3 3 3 3

For additional information about what drugs are on our 2026 formulary, please visit our plan's website at https://www.amerihealthcaritasvipcare.com/pa/provider. For any additional questions, please contact Provider Services at 1-800-521-6007.